Clinical trials: Demyelinating Disorder
Multiple Sclerosis
FOCUS Fatigue Outcome in Copaxone USers
The study primarily investigates the effect of copaxone on fatigue during treatment, compared to baseline in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT00267319
- Testing
- Glatiramer acetate
- Where
- Czechia
- Volunteers
- 111 people
- Sponsor
- Sanofi
Relapsing-Remitting Multiple Sclerosis
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
This is a 1 year study to evaluate the efficacy, safety, and tolerability of Tovaxin T cell therapy in subjects with a clinically isolated syndrome (CIS) and relapse-remitting multiple sclerosis (RR-MS).
- Trial name
- TERMS (NCT00245622)
- Testing
- Tovaxin Autologous T cell vaccine
- Where
- 33 sites in United States
- Volunteers
- 150 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
- Trial name
- NCT06384976
- Testing
- KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Kyverna Therapeutics
Multiple Sclerosis, Relapsing-Remitting
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device).
- Trial name
- NCT02652091
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
- Where
- 23 sites in United States
- Volunteers
- 146 people
- Sponsor
- Bayer
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no…
- Trial name
- NCT05028634
- Testing
- Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
- Where
- 33 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Celgene
Multiple Sclerosis
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS).
- Trial name
- TEMSO (NCT00134563)
- Testing
- Teriflunomide
- Where
- 21 sites in United States, Austria and 19 more
- Volunteers
- 1,088 people
- Sponsor
- Sanofi
Walking Impairment, Multiple Sclerosis
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the…
- Trial name
- NCT02471222
- Testing
- ADS-5102
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Multiple Sclerosis
Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis.
- Trial name
- NCT00381264
- Testing
- Cesamet™ (nabilone)
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- NEMA Research, Inc.
Relapsing Forms of Multiple Sclerosis
Plegridy Observational Program
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term…
- Trial name
- POP (NCT02230969)
- Testing
- peginterferon beta-1a
- Where
- 152 sites in United States, Australia and 12 more
- Volunteers
- 1,208 people
- Sponsor
- Biogen
Secondary Progressive Multiple Sclerosis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).
- Trial name
- ASCEND in SPMS (NCT01416181)
- Testing
- natalizumab
- Where
- 161 sites in United States, Belgium and 15 more
- Volunteers
- 889 people
- Sponsor
- Biogen
Multiple Sclerosis
Safety Study of GNbAC1 in Multiple Sclerosis Patients
The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.
- Trial name
- NCT01639300
- Testing
- GNbAC1
- Where
- 2 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- GeNeuro Innovation SAS
Muscle Spasticity
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following…
- Trial name
- NCT00358293
- Testing
- Tizanidine (sublingual or oral)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Teva GTC
Relapsing Remitting Multiple Sclerosis
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs.
- Trial name
- EPOC (NCT01317004)
- Testing
- Fingolimod, Standard MS DMT
- Where
- 17 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Cerebral Adrenoleukodystrophy (CALD)
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
The purpose of this study is to evaluate the efficacy and safety of Lenti-D Drug Product (also known as elivaldogene autotemcel or Skysona, hereafter referred to as eli-cel) after myeloablative conditioning with busulfan and…
- Trial name
- NCT03852498
- Testing
- Lenti-D
- Where
- 8 sites in United States, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Genetix Biotherapeutics Inc.
Multiple Sclerosis
LEMTRADA Pregnancy Registry in Multiple Sclerosis
Primary Objective: The primary goal of this registry is to assess the risk of spontaneous abortion in prospective enrolled women exposed to LEMTRADA for multiple sclerosis.
- Trial name
- NCT03774914
- Testing
- Alemtuzumab (GZ402673)
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Relapsing Remitting Multiple Sclerosis (RRMS)
RNF and Betaseron® Tolerability Study
To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes…
- Trial name
- REFORMS (NCT00428584)
- Testing
- New Formulation of rebif - human interferon beta-1a, Interferon beta -1b
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- EMD Serono
Relapsing Remitting Multiple Sclerosis
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with…
- Trial name
- NCT01037907
- Testing
- Pleneva TM BGC20-0134
- Where
- 35 sites in Belgium, France and 4 more
- Volunteers
- 173 people
- Sponsor
- Boston Scientific Corporation
Multiple Sclerosis
Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies
This retrospective, observational cohort study used administrative claims data contained in the International Business Machines (IBM)® Truven Marketscan® Research Databases to describe demographic, clinical, and treatment…
- Trial name
- NCT06459232
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Novartis
Multiple Sclerosis
A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.
- Trial name
- NCT01318421
- Testing
- ELND002
- Volunteers
- 12 people
- Sponsor
- Elan Pharmaceuticals
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.